EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical and molecular significance of the RNA m6A methyltransferase complex in prostate cancer

Jennifer Lothion-Roy, Daisy B Haigh, Anna E Harris, Veronika M Metzler, Mansour Alsaleem, Michael S Toss, Yousif Kariri, Atara Ntekim, Brian D Robinson, Francesca Khani, Lorraine J Gudas, Cinzia Allegrucci und 11 weitere

Frontiers in Genetics · 12.01.2023 · 13

DOI: 10.3389/fgene.2022.1096071 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Genetics, online erschienen am 12.01.2023. Verfasst von Jennifer Lothion-Roy und 22 weiteren Autor:innen. Beteiligte Einrichtung: Biodiscovery Institute, University of Nottingham, Nottingham, United Kingdom. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

N 6 -methyladenosine (m 6 A) is the most abundant internal mRNA modification and is dynamically regulated through distinct protein complexes that methylate, demethylate, and/or interpret the m 6 A modification. These proteins, and the m 6 A modification, are involved in the regulation of gene expression, RNA stability, splicing and translation. Given its role in these crucial processes, m 6 A has been implicated in many diseases, including in cancer development and progression. Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer in men and recent studies support a role for m 6 A in PCa. Despite this, the literature currently lacks an integrated analysis of the expression of key components of the m 6 A RNA methyltransferase complex, both in PCa patients and in well-established cell line models. For this reason, this study used immunohistochemistry and functional studies to investigate the mechanistic and clinical significance of the METTL3, METTL14, WTAP and CBLL1 components of the m 6 A methyltransferase complex in PCa specimens and cell lines. Expression of METTL3 and CBLL1, but not METTL14 and WTAP, was associated with poorer PCa patient outcomes. Expression of METTL3, METTL14, WTAP and CBLL1 was higher in PCa cells compared with non-malignant prostate cells, with the highest expression seen in castrate-sensitive, androgen-responsive PCa cells. Moreover, in PCa cell lines, expression of METTL3 and WTAP was found to be androgen-regulated. To investigate the mechanistic role(s) of the m 6 A methyltransferase complex in PCa cells, short hairpin RNA (shRNA)-mediated knockdown coupled with next generation sequencing was used to determine the transcriptome-wide roles of METTL3, the catalytic subunit of the m 6 A methyltransferase complex. Functional depletion of METTL3 resulted in upregulation of the androgen receptor (AR), together with 134 AR-regulated genes. METTL3 knockdown also resulted in altered splicing, and enrichment of cell cycle, DNA repair and metabolic pathways. Collectively, this study identified the functional and clinical significance of four essential m 6 A complex components in PCa patient specimens and cell lines for the first time. Further studies are now warranted to determine the potential therapeutic relevance of METTL3 inhibitors in development to treat leukaemia to benefit patients with PCa.

Schlagwörter

Stichwörter der Autor:innen

CBLL1METTL14METTL3WTAPsplicingtranscriptome

Autor:innen und Institutionen

  • Biodiscovery Institute, University of Nottingham, Nottingham, United Kingdom.
  • School of Veterinary Medicine and Sciences, University of Nottingham, Sutton Bonington Campus, Loughborough, United Kingdom.
  • School of Medicine, University of Nottingham, Nottingham, United Kingdom.
  • Department of Applied Medical Science, Applied College, Qassim University, Qassim, Saudi Arabia.
  • Department of Clinical Laboratory Science, Faculty of Applied Medical Science, Shaqra University, Shaqra, Saudi Arabia.
  • Department of Radiation Oncology, University Hospital Ibadan, University of Ibadan, Ibadan, Nigeria.

Zitieren

APA

Lothion-Roy, J., Haigh, D. B., Harris, A. E., Metzler, V. M., Alsaleem, M., Toss, M. S., Kariri, Y., Ntekim, A., Robinson, B. D., Khani, F., Gudas, L. J., Allegrucci, C., James, V. H., Madhusudan, S., Mather, M., Emes, R. D., Archer, N., Fray, R. G., Rakha, E., …, & Woodcock, C. L. (2023). Clinical and molecular significance of the RNA m6A methyltransferase complex in prostate cancer. Frontiers in Genetics, 13. https://doi.org/10.3389/fgene.2022.1096071

Vancouver

Lothion-Roy J, Haigh DB, Harris AE, Metzler VM, Alsaleem M, Toss MS, et al. Clinical and molecular significance of the RNA m6A methyltransferase complex in prostate cancer. Frontiers in Genetics. 2023;13. doi:10.3389/fgene.2022.1096071

BibTeX
@article{LothionRoy2023,
  author = {Lothion-Roy, Jennifer and Haigh, Daisy B and Harris, Anna E and Metzler, Veronika M and Alsaleem, Mansour and Toss, Michael S and Kariri, Yousif and Ntekim, Atara and Robinson, Brian D and Khani, Francesca and Gudas, Lorraine J and Allegrucci, Cinzia and James, Victoria H and Madhusudan, Srinivasan and Mather, Melissa and Emes, Richard D and Archer, Nathan and Fray, Rupert G and Rakha, Emad and Jeyapalan, Jennie N and Rutland, Catrin S and Mongan, Nigel P and Woodcock, Corinne L},
  title = {Clinical and molecular significance of the RNA m6A methyltransferase complex in prostate cancer},
  journal = {Frontiers in Genetics},
  year = {2023},
  volume = {13},
  doi = {10.3389/fgene.2022.1096071}
}
Kostenlos starten →